American Century Companies Inc. Buys 95,066 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

American Century Companies Inc. lifted its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 124.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 171,590 shares of the biotechnology company’s stock after purchasing an additional 95,066 shares during the period. American Century Companies Inc.’s holdings in Aurinia Pharmaceuticals were worth $1,541,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after acquiring an additional 64,949 shares during the last quarter. Barclays PLC lifted its position in Aurinia Pharmaceuticals by 187.6% during the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after purchasing an additional 143,072 shares in the last quarter. Blue Trust Inc. lifted its position in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Aurinia Pharmaceuticals by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after purchasing an additional 89,940 shares during the period. Finally, Atria Wealth Solutions Inc. purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter worth about $135,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Stock Up 5.7 %

Shares of Aurinia Pharmaceuticals stock opened at $7.61 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -50.73 and a beta of 1.20. The firm’s 50-day moving average is $8.04 and its two-hundred day moving average is $8.09. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Insider Activity at Aurinia Pharmaceuticals

In related news, insider Greg Keenan sold 12,239 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the transaction, the insider now owns 161,789 shares of the company’s stock, valued at approximately $1,294,312. This represents a 7.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at $15,631,136. This represents a 9.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock valued at $2,753,094 in the last three months. 4.30% of the stock is owned by insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.